Rezolute is trading 5.11% down at $4.17 after announcing on September 9, 2026, that the FDA is still reviewing Phase 3 sunRIZE data without a specific timeline for regulatory feedback.
- The study previously missed its primary and key secondary endpoints, leaving the company awaiting a potential regulatory path for ersodetug in congenital hyperinsulinism.
- Broader markets are also modestly lower.
- Rezolute continues recruiting for upLIFT and expects topline results before the end of 2026.